Literature DB >> 12631417

Inhibition of TPA-induced NF-kappaB nuclear translocation and production of NO and PGE2 by the anti-rheumatic gold compounds.

Masamichi Yamashita1, Shigeru Ashino, Yuko Oshima, Shunsuke Kawamura, Kazuo Ohuchi, Motoaki Takayanagi.   

Abstract

Auranofin, aurothioglucose and aurothiomalate (10 microM each) inhibited 12-O-tetradecanoylphorbol 13-acetate (TPA, 16.2 nM)-induced nuclear translocation of nuclear factor-kappa B (NF-kappaB), and production of nitric oxide (NO) and prostaglandin E(2) (PGE(2)) in rat peritoneal macrophages when the cells were pre-incubated with each gold compound for 20 h. Without pre-incubation for 20 h, aurothioglucose and aurothiomalate, but not auranofin, failed to inhibit the TPA-induced NF-kappaB nuclear translocation and production of NO and PGE(2). Auranofin, aurothioglucose and aurothiomalate did not affect the direct binding of NF-kappaB to the DNA probe. It was suggested that these gold compounds inhibit the TPA-induced production of NO and PGE(2) by inhibiting the NF-kappaB nuclear translocation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631417     DOI: 10.1211/002235702513

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  10 in total

1.  Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.

Authors:  Hyung S Youn; Joo Y Lee; Shin I Saitoh; Kensuke Miyake; Daniel H Hwang
Journal:  Biochem Biophys Res Commun       Date:  2006-09-28       Impact factor: 3.575

Review 2.  Protein kinase Cι expression and oncogenic signaling mechanisms in cancer.

Authors:  Nicole R Murray; Krishna R Kalari; Alan P Fields
Journal:  J Cell Physiol       Date:  2011-04       Impact factor: 6.384

Review 3.  Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.

Authors:  Alan P Fields; Roderick P Regala
Journal:  Pharmacol Res       Date:  2007-05-05       Impact factor: 7.658

4.  Phenolic fraction of tobacco smoke condensate potentiates benzo[a]pyerene diol epoxide-induced cell transformation: role of protein kinase C.

Authors:  Jagat J Mukherjee; Subodh Kumar
Journal:  Mutat Res       Date:  2009-12-16       Impact factor: 2.433

5.  Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.

Authors:  S Talbot; R Nelson; W T Self
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

6.  Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

Authors:  Aaron S Mansfield; Alan P Fields; Aminah Jatoi; Yingwei Qi; Alex A Adjei; Charles Erlichman; Julian R Molina
Journal:  Anticancer Drugs       Date:  2013-11       Impact factor: 2.248

Review 7.  Aspirin Intolerance: Experimental Models for Bed-to-Bench.

Authors:  Masamichi Yamashita
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

8.  Auranofin Resistance in Toxoplasma gondii Decreases the Accumulation of Reactive Oxygen Species but Does Not Target Parasite Thioredoxin Reductase.

Authors:  Christopher I Ma; James A Tirtorahardjo; Sharon Jan; Sakura S Schweizer; Shawn A C Rosario; Yanmiao Du; Jerry J Zhang; Naomi S Morrissette; Rosa M Andrade
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

9.  Anti-Inflammatory Effect of Auranofin on Palmitic Acid and LPS-Induced Inflammatory Response by Modulating TLR4 and NOX4-Mediated NF-κB Signaling Pathway in RAW264.7 Macrophages.

Authors:  Hyun Hwangbo; Seon Yeong Ji; Min Yeong Kim; So Young Kim; Hyesook Lee; Gi-Young Kim; Suhkmann Kim; JaeHun Cheong; Yung Hyun Choi
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

10.  The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma.

Authors:  C Q Ma; Y Yang; J M Wang; G S Du; Q Shen; Y Liu; J Zhang; J L Hu; P Zhu; W P Qi; Y W Qian; Y Fu
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.